The LSI Alumni 2025 Funding Report is now updated with all deals from Q1. In Q1 of 2025, LSI Alumni raised over $1.37 billion across 45 deals. Our quarterly Alumni Funding Report features transactions made by these medical device startups and their investors, as well as links to our proprietary media and coverage of the companies.

Companies featured in the Q1 2025 update include:

4C Medical Technologies 

Secured $175M in Series D funding to support the continued development of its transcatheter mitral valve replacement (TMVR) device, the AltaValve System. Proceeds will help advance the ongoing ATLAS pivotal trial across the U.S. and Europe.

Aescape

Raised $83M in strategic funding to accelerate U.S. expansion and scale production of its AI-powered robotic massage therapy system. The capital will also support the company’s nationwide launch through a newly announced partnership with Equinox.

Approxima

Closed the first tranche of its €7.3M Series A round to progress its minimally invasive right ventricular reshaping technology for tricuspid regurgitation. The investment will fund preclinical validation efforts, initial human studies, and preparation for a U.S.-based Early Feasibility Study.

Arcuro Medical

Announced the first close of its Series A round, led by Varana Capital, to drive its next stage of development. The company is advancing the SuperBall Meniscal Repair System—an all-suture, knotless solution that replicates the tensioning benefits of inside-out meniscal repair techniques.

Aspect Biosystems

Closed a $115M Series B round led by Dimension to further its bioprinted tissue therapeutics platform. The investment will support the clinical advancement of multiple regenerative medicine solutions.

Berlin Heals

Raised over CHF 7M to initiate first-in-human studies for its minimally invasive C-MIC implant procedures. The financing will also support CE submission for the first-generation device and lay the groundwork for a pivotal trial to secure global regulatory and reimbursement approvals.

Brainomix

Closed a £14M ($18M) Series C funding round to accelerate U.S. expansion of its AI-driven imaging tools for stroke and lung fibrosis. The investment will also support the advancement of its broader technology portfolio aimed at faster diagnoses and greater access to critical treatments.

Cagent Vascular

Received $15M in growth financing from Trinity Capital to support commercial expansion. The funding will fuel broader market adoption of the company’s Serranator angioplasty balloon.

CeQur

Completed a $120M equity raise to drive commercial expansion. The investment will be used to broaden access to the company’s four-day wearable insulin delivery system for individuals managing diabetes.

EBAmed

Secured funding from CDP Venture Capital through Italy’s PNRR and the Next Generation EU program. The support will help advance development of CardioKit, the company’s non-invasive ultrasound-based system for treating cardiac arrhythmias.

Endovascular Engineering

Completed a $42M oversubscribed Series B round to propel development of its thrombectomy system for pulmonary embolism. The investment will fund ongoing clinical studies and regulatory initiatives supporting its path to market.

Exero Medical

Closed a $12.7M preferred seed round to advance its breakthrough-designated xBar system for post-operative tissue healing. The funding will support the completion of its FDA pivotal trial and preparation for U.S. launch.

Field Medical

Raised $26.87M in fresh funding after receiving FDA TAP Pilot acceptance and Breakthrough Device Designation for its FieldForce Ablation System in December 2024. FieldForce is the first pulsed-field ablation (PFA) platform purpose-built for treating ventricular arrhythmias.

Flosonics Medical

Raised $7.5M CAD in venture debt from RBCx to support the expansion of FloPatch, a wireless wearable Doppler ultrasound designed for fluid monitoring in critical care settings. The funding will help drive adoption across hospitals, supporting improved sepsis care, fewer complications, and better patient outcomes.

Francis Medical

Closed an $80M oversubscribed Series C equity round to support the advancement of its water vapor ablation platform for prostate, kidney, and bladder cancers. The proceeds will fund ongoing clinical trials and help accelerate commercial expansion.

Gleamer

Acquired Pixyl and Caerus Medical to broaden its AI imaging capabilities with MRI tools for neurology and musculoskeletal applications. With this expansion, the company became the only AI imaging provider spanning X-ray, mammography, CT, and MRI—strengthening its position in radiology automation and clinical decision support.

GT Medical Technologies

Closed a $37M Series D round to broaden U.S. access to GammaTile, a therapy for patients undergoing surgery for brain tumors. The capital will also back clinical research initiatives and help scale commercialization efforts.

ImpediMed

Established a five-year $15M growth capital agreement with SWK Holdings to accelerate commercial initiatives. ImpediMed is the company behind the SOZO Digital Health Platform, the only FDA-cleared bioimpedance spectroscopy (BIS) technology for evaluating breast cancer-related lymphedema.

IQ Endoscopes

Raised new funding from BGF and the Development Bank of Wales to accelerate the introduction of its eco-friendly, single-use endoscopy system. The capital will aid early implementation across four UK health centers beginning in July 2025, with the goal of increasing clinical efficiency and minimizing cross-contamination risks.

iotaMotion

Completed its Series B funding round to advance commercialization efforts. The company’s iotaSOFT system is the first and only robotic-assisted platform in the U.S. designed for cochlear implant electrode array insertion.

Madison Scientific

Raised $7M in seed financing to support the advancement of its SmartShunt technology for hydrocephalus care. The investment will help grow the Madison Scientific team, progress preclinical studies, and refine prototype development for its novel management system.

MicroTransponder

Closed a $65M Series F funding round to accelerate the adoption of its Vivistim Paired VNS Therapy, aimed at improving stroke rehabilitation outcomes. Vivistim is currently the only FDA-cleared device shown to significantly enhance upper limb function in chronic ischemic stroke patients beyond what is achieved with high-intensity rehabilitation alone.

Nervonik

Closed a $13M Series A round to further develop its peripheral nerve stimulation system targeting chronic pain management. The investment will be used to support clinical validation and regulatory milestones as the company moves toward market entry with its neuromodulation platform.

Neuro Event Labs

Raised €2M to support European growth and prepare for U.S. entry of its AI-driven seizure detection solution, Nelli. The CE-marked, MDR-certified technology improves epilepsy monitoring in both clinical and home environments, with a U.S. debut anticipated later this year.

Neuronoff

Secured $5M in combined funding from the DOD and NIH to further develop its Injectrode neuromodulation platform. The DOD grant will fund a randomized controlled trial for neurogenic bladder post-spinal cord injury, while NIH support will back preclinical studies for overactive bladder treatment.

Newronika

Closed a €13.6M Series B round led by new investor Fondazione ENEA Tech e Biomedical to advance its adaptive deep brain stimulation (aDBS) technology. The financing will support clinical validation efforts and drive commercialization of the platform.

Noah Labs

Was awarded €11M by the European Innovation Council (EIC) Accelerator, comprising €2.5M in grants and up to €8.5M in potential equity funding. The support will advance development of the company’s AI-driven speech analysis platform, designed to enable early detection of heart failure and transform remote cardiac monitoring.

Nurami Medical

Completed a $30M financing round to advance its meningeal tissue repair platform for use in brain and spinal cord procedures. The capital will be used to expand research and development efforts and scale manufacturing to support increasing clinical demand.

Onkos Surgical

Secured a $35M venture loan facility from Horizon Technology Finance to accelerate the commercialization of its NanoCEPT antibacterial implant technology. The funds will also support the company’s efforts to expand manufacturing capabilities and drive adoption across orthopedic markets.

Paradromics

Disclosed a new strategic investment from NEOM, Saudi Arabia’s innovation-focused initiative for sustainable development. The collaboration will help advance brain-computer interface (BCI) healthcare technologies across the MENA region.

Perfuze

Raised €22M in additional funding to support the commercialization and clinical development of its neurovascular access technologies. The new capital will help Perfuze expand operations and bring its stroke treatment devices to more patients worldwide.

Phoenix DeVentures

Shared plans to be acquired by INDO-MIM Ltd., a global precision manufacturing leader, and rebrand under the name PDV MedTech. The deal is expected to strengthen innovation capabilities, expand service offerings, and boost manufacturing quality and efficiency through greater global resources.

PulmoTech

Has been acquired by Sentec. The acquisition strengthens Sentec’s commitment to improving outcomes and reducing clinical burdens in respiratory care through innovative, cost-effective technologies.

Pulnovo Medical

Raised close to $100M in Series C funding to further the development of its pulmonary artery denervation (PADN) therapy for pulmonary hypertension and heart failure. The investment will be used to support clinical trials, regulatory efforts, and global market expansion.

Quibim

Closed a $50M Series A financing round with participation from lead investors Asabys and Buenavista. The capital will be used to expand Quibim’s AI-powered product portfolio and accelerate its commercial strategy.

Robeauté

Secured $28M in funding to further the development of its microrobotic neurosurgery platform. The investment will help prepare for first-in-human trials slated for 2026 and support the launch of U.S. operations in anticipation of regulatory clearance and commercialization.

ScreenPoint Medical

Acquired BioMediq A/S to enhance breast cancer risk evaluation tools within its product portfolio. The integration will strengthen ScreenPoint’s Transpara platform by incorporating advanced risk assessment capabilities.

Shoulder Innovations

Completed a $40M Series E equity raise to support the commercial rollout of its InSet Total Shoulder and Reverse Shoulder Arthroplasty platforms. The funding will also back ongoing innovation and expansion within the shoulder replacement space.

StarTric

Received a €2.5M grant from the European Innovation Council (EIC) and up to €8.4M in equity support to propel the development of TriClover, a minimally invasive solution for tricuspid valve repair. The funding will accelerate clinical evaluation and help advance the therapy toward commercialization for patients with tricuspid regurgitation.

Vektor Medical

Completed a $25M oversubscribed Series A round to accelerate the growth of its AI-driven arrhythmia mapping platform, vMap. The funds will be used to expand commercial activities, conduct further clinical studies, and support entry into the European market.

VitalConnect

Raised $100M to advance the expansion of its remote patient monitoring platform. The capital will be used to ramp up production and drive broader adoption of its wearable biosensor technology.

VQ Biomedical

Secured $5M in funding to further develop its catheter-based technology for delivering oxygen directly into the bloodstream in patients with ARDS. Backing from Harbright Ventures, Duke Capital Partners, DARPA, and others will help drive product advancement and upcoming clinical studies.

XARlabs

Raised $2.3M in seed funding, led by Eric Johnson with participation from EKA Ventures, to support international expansion of its simXAR platform. The investment will fuel further development of the company’s mixed-reality technology, which enhances surgical planning and training through immersive 3D visualization.

Zeto

Closed a $31M Series B funding round to further develop its wireless EEG headset and cloud-based platform. The capital will be used to expand commercial and operational teams, support market growth, and advance research and development efforts.

More News

Stay tuned for more updates as these medical technology companies continue to innovate and lead the way in the medtech industry. As we look forward to LSI Asia '25 in Singapore this June, these achievements remind us of the incredible progress being made in the medtech sector.